
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

FORM 6-K

**REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934**

For the month of January 2023

Commission File Number: 001-41562

NewAmsterdam Pharma Company N.V.
(Exact name of registrant as specified in its charter)

**Gooimeer 2-35
1411 DC Naarden
The Netherlands**
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

On January 10, 2023, NewAmsterdam Pharma Company N.V. (the “Company”) received a notice from the Listing Qualifications Department of the Nasdaq Stock Market LLC, notifying the Company that its application to upgrade the listing of its ordinary shares from The Nasdaq Capital Market to The Nasdaq Global Market (the “Global Market”) has been approved. The Company’s ordinary shares will begin trading, with the same trading symbol, on the Global Market effective with the open of business on January 12, 2023.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

January 11, 2023

NewAmsterdam Pharma Company N.V.

By: /s/ David Topper

Name: David Topper

Title: Chief Financial Officer